

# ESHRE 2021

## Abstracts Highlighting FERRING Data

---

### O-109 / 29 June 10:00 CEST

**A first dose-response trial investigating the effects of adding choriogonadotropin beta to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol**

*M. Fernández-Sánchez, H. Višnová, C. Blockeel, A. Pinborg, Y. Khalaf, P. Larsson, B. Mannaerts*

### O-110 / 29 June 10:15 CEST

**A randomised, controlled, assessor-blind trial assessing clinical outcomes of individualised dosing with follitropin delta in Asian IVF/ICSI patients**

*J. Qiao, Y. Zhang, X. Liang, T. Ho, H.Y. Huang, S.H. Kim, M. Goethberg, B. Mannaerts, J.-C. Arce, Asian Follitropin Delta Phase 3 Trial - GRAPE*

### O-114 / 29 June 11:15 CEST

**Improved safety and efficiency of individualised versus conventional gonadotropin dosing for ovarian stimulation in IVF/ICSI: an individual patient meta-analysis (IPDMA)**

*F. Janse, M. Eijkemans, B. Fauser*

#### Legend

- e-poster (P)
- oral presentation (O)

### P - 587

**Highly purified human menopausal gonadotrophin (HP-hMG, Menopur) as a ready-to-use solution for injection in pre-filled pen is bioequivalent to HP-hMG powder for reconstitution**

*D.M. Jonker, M. Koch, P. Larsson, A. Ravi, B. Buur Rasmussen, R. Speer, B. Mannaerts*

### P - 586

**Clinical outcome in frozen cycles using cryopreserved blastocysts derived from ovarian stimulation with follitropin delta**

*J. Havelock, J.-C. Arce, ESTHER-1 and ESTHER-2*

### P - 132

**Centralized versus local embryologists scoring of blastocyst quality obtained in a large European multicenter clinical trial**

*M. Montag, E. Van den Abbeel, T. Ebner, P. Larsson, B. Mannaerts*

### P - 650

**Body weight is the main determinant of systemic follicle stimulating hormone (FSH) concentrations during controlled ovarian stimulation with follitropin delta.**

*D.M. Jonker*